Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus IMIPRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus IMIPRAMINE HYDROCHLORIDE.
AVENTYL HYDROCHLORIDE vs IMIPRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline hydrochloride, the active ingredient in Aventyl Hydrochloride, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has antihistaminic, anticholinergic, and sedative properties.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their synaptic concentrations. Also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum dose 150 mg/day.
Initial 75 mg/day orally in divided doses, increase to 150-200 mg/day; maximum 300 mg/day. For maintenance, 50-150 mg/day orally.
None Documented
None Documented
Terminal elimination half-life is approximately 19–24 hours; may be prolonged in elderly and patients with hepatic impairment.
Terminal half-life 11-25 hours (mean ~20 h); clinical context: steady-state achieved in ~1 week, dosing adjustment needed in hepatic impairment
Primarily renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal excretion accounts for ~30%.
Renal (70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant